Background
==========

Two-component regulatory systems (TCRS) are the most abundant and widespread transcriptional regulators in bacteria, as indicated by the number of instances of the Pfam PF00072 response regulator receiver domain \[[@B1]\]. Bacterial genomes typically contain dozens to hundreds of these systems \[[@B2]\]. Response regulator domains of transcriptional regulatory proteins are phosphorylated by cognate sensor histidine kinase proteins in response to changes in environment or growth conditions \[[@B3]\]. This phosphorylation results in conformational change of the response regulator protein, leading to transcriptional activation or repression. Even with the recognized importance of these systems, very few of them have been characterized with regard to the signal input and the regulatory targets.

The ExoS/ChvI two-component regulatory system, consisting of the membrane-spanning histidine protein kinase ExoS and the response regulator ChvI, is found in alphaproteobacterial genomes. In *Agrobacterium tumefaciens*, the ChvG/ChvI system is vital for plant tumor formation, and mutants are sensitive to acidic pH and detergents \[[@B4]\]. The BvrS/BvrR system of *Brucella abortus* is required for virulence \[[@B5]\] and has a broad impact on cell envelope as well as carbon and nitrogen metabolism \[[@B6]\]. The *Bartonella henselae* BatR/BatS system is also involved in regulating virulence-associated genes \[[@B7]\]. Analysis of a mutant of the ExoS homolog of *Rhizobium leguminosarum* confirmed its requirement for successful nodule invasion and nitrogen fixation \[[@B8]\]. This mutant also had a destabilized outer membrane, associated with reduction of *ropB* expression, as well as increased accumulation of intracellular poly-3-hydroxybutrate (PHB), and reduction in exopolysaccharide production. In all cases studied, ExoS/ChvI TCRS and its orthologs play a role, although not well understood, in the bacterial-host interaction.

*Sinorhizobium meliloti exoS* was first identified through a Tn*5* insertion mutant that resulted in overproduction of exopolysaccharide due to disruption of the membrane-spanning portion of the protein, causing constitutive activation of the kinase activity, thus resulting in constant phosphorylation of ChvI \[[@B9]\]. Null mutants of *exoS* and *chvI* are able to trigger the formation of nodules, but those nodules do not develop normally and they do not fix nitrogen \[[@B10]\]. The mutants do not grow on complex or in liquid media, and cultivation on defined agar-media is challenging, a condition that prompted an early conclusion that *exoS* and *chvI* are essential for *S. meliloti* viability \[[@B11]\]. A *chvI* deletion mutant demonstrated enhanced motility, and reduction in PHB accumulation, the opposite of what was found for a *R. leguminosarum exoS* homolog mutant \[[@B12]\]. Similar to the *R. leguminosarum* mutant \[[@B8]\], alterations in LPS were observed. Also isolated in the Tn*5* screen that yielded the constitutively activated exopolysaccharide overproducing *exoS* mutant was a mutant of *exoR*\[[@B9]\]. Evidence has been provided to suggest a direct interaction of ExoR with ExoS in the periplasm, with ExoR binding contributing to the maintenance of ExoS in an inactive conformation \[[@B13]\]. Furthermore, it has been proposed that cleavage of ExoR is induced by some yet unknown environmental signal during infection of the host plant, and this might modulate its ability to bind ExoS \[[@B14]\], resulting in its activation and regulation of the target genes.

The *exoS* gene is situated within an operon along with *hprK*, part of an incomplete phosphotransferase system (PTS) in Alphaproteobacteria. In *S. meliloti,* HprK is involved in succinate mediated catabolite repression \[[@B15]\]. The establishment of a direct functional or regulatory link between the incomplete PTS and the ExoS/ChvI TCRS has been elusive, partly because the systems have often been studied in isolation.

Given the pleotropic nature of the *exoS* and *chvI* null mutants \[[@B10]\], investigation of gene expression using transcriptomics and proteomics might prove less than satisfactory, as the expression of many genes that are not direct regulatory targets is likely to be altered due to physiological changes in the cell. Indeed transcriptomics have identified hundreds of genes whose expression is affected by the *exoS96*::Tn*5* mutation \[[@B16]\]. Comparison of transcriptomes from two different *chvI* mutant strains (gain-of-function versus reduced-function) narrowed the set of genes regulated by ChvI and subsequently facilitated the identification by gel shift assays of three intergenic regions binding ChvI \[[@B17]\] and the determination of an 11-bp-long putative ChvI binding motif. However, for the majority of genes identified as being differentially expressed in a ChvI dependent manner in that study, including the succinoglycan synthesis genes, no binding to upstream regions could be demonstrated. As an alternative, we applied a method to screen for DNA fragments that were directly bound by the ChvI transcriptional regulator. Analysis of these targets suggests important metabolic pathways affected by ChvI regulation. In return, these new findings directed us to uncover better conditions for cultivation of the loss-of-function *chvI* mutants. Further analyses with reporter gene fusion assays confirmed the direct role of ChvI as a repressor for the rhizobactin and SMc00261 operons. It also confirmed the previously discovered direct activation of the *msbA2* operon by ChvI. Methods developed here to identify ChvI targets have proved to be efficient and could be applied to other response regulators.

Results
=======

Application of electrophoretic mobility shift assay to the identification of ChvI-regulated genes
-------------------------------------------------------------------------------------------------

To better understand the role of ChvI as a response regulator, it is necessary to identify genes whose transcription is directly influenced by ChvI. To identify specific DNA sequences from plasmid or genomic DNA for which ChvI might have binding affinity, we adapted a method using the electrophoretic mobility shift principle \[[@B18]\]. The plasmid DNA electrophoretic mobility shift assay (PD.EMSA) and genomic DNA electrophoretic mobility shift assay (GD.EMSA) methods involve incubation of purified DNA-binding protein with fractionated DNA, followed by electrophoresis through a native polyacrylamide gel using sodium boric acid (SB) buffer. In this study, the restriction endonuclease Bsp143I was used for DNA fragmentation. The use of SB buffer, a low conductivity medium, and a 14-cm gel as well as running the gel for 3--6 hours at low voltage, allowed unbound DNA fragments to migrate far from the top of the gel while ChvI-bound fragments remained near the wells (see Additional file [1](#S1){ref-type="supplementary-material"}). Inclusion of EDTA in the buffer resulted in no retardation of electrophoretic mobility suggesting an involvement of the putative Mg^2+^ site for ChvI-DNA interaction (see Additional file [2](#S2){ref-type="supplementary-material"}). The slower migrating bands were excised from the gel, purified, and cloned into pUC18 vector from which the insert DNA could be sequenced from each end to determine the extent of each fragment.

Bsp143I-digested pTC198 plasmid DNA was used to perform PD.EMSA (see Additional file [1](#S1){ref-type="supplementary-material"}). This pUC19 clone contains a 5-kb KpnI-fragment from *S. meliloti* Rm1021 spanning across the entire *chvI-hprK* genomic sequence including the intergenic region between *pckA* and *chvI*\[[@B10]\]. This plasmid was employed to optimize the method with a smaller number of fragments than with genomic DNA, thus providing a better resolution on the gel but also increasing the chances of binding to areas surrounding *chvI* and *exoS* to test for possible autoregulation of ExoS/ChvI. Regulation of the adjacent gene *pckA* by *chvG-chvI* has been previously shown for *A. tumefaciens* using reporter gene fusion assays \[[@B19]\], therefore this experiment was also aimed at testing if *S. meliloti* ChvI could bind upstream of *pckA*.

Following the excision of electrophoretic bands from PD.EMSA of pTC198, DNA fragments were cloned into BamHI-linearized pUC18 and sequenced from both ends. Out of four inserts sequenced, three represent a 176-bp fragment (genomic origin from 48523 to 48699) coding for the region upstream of SMc02753, including its start codon. A single clone contained a 395-bp region spanning the upstream sequence of *chvI* and past the translational start site (genomic origin from 51887 to 52281). These results suggest that ChvI might autoregulate its transcription but most importantly, it shows a direct binding affinity between the ChvI and the upstream sequence of *manXhpr* operon part of the PTS system. The ChvI binding to the 176-bp fragment was also confirmed by performing a gel shift assay using a PCR-amplified DNA fragment from pLB102 and the purified ChvI protein (data not shown). Further delineation of this binding was not performed.

After GD.EMSA, the examination of 27 clones resulted in the identification of a large number of additional potential targets for ChvI regulation (Table [1](#T1){ref-type="table"}). Fragments ranged in size from 67 bp to 595 bp. Interestingly, the majority of fragments identified were found to be in predicted coding sequences rather than in intergenic regions. Moreover, ChvI-binding fragments are widely distributed across the genome and are not confined to a particular metabolic pathway. Although no one fragment was identified more than once, two non-contiguous fragments that are part of the same gene (*rhtX*) were independently cloned and sequenced. Fragments from the *exoS-chvI* region were not among the sequenced clones. Reporter gene fusions were used to confirm the *chvI*-regulated transcription of three selected genes (see below). These genes were selected based on their availability from a random fusion library \[[@B20]\], to test a mix of inter and intra fragments and to validate the previously described regulation of the *msbA2* gene cluster.

###### 

DNA fragments recovered from GD.EMSA and genes potentially regulated by ChvI

  **Fragment**   **Size**   **Genomic origin**   **Position**   **Gene**        **Function**                   
  -------------- ---------- -------------------- -------------- --------------- ------------------------------ ---------------------------------------------------------------------------------------------
                            ***Chromosome***                                                                   
  F1             129        60821                60949          intra           SMc02574 (*hisB*)              probable imidazoleglycerol-phosphate dehydratase
  F2             304        654156               654459         intra           SMc02281                        
  F3             595        1085493              1086087        intra           SMc00051 (*phaA2*)             probable Na(+)/H(+)-antiporter (upstream *mucR*)
  F4             152        1183131              1183282        intra           SMc02637                       (upstream *lpsL and rkpK*)
  F5             139        1220301              1220439        intra           SMc00550                       ABC transporter ATP-binding transmembrane protein (upstream *psd* and *pssA*)
  F6             142        1260626              1260767        intra           SMc00589                       (upstream *gal*)
  F7             145        1639710              1639854        intra           SMc02076 (*cls*)               putative cardiolipin synthetase transmembrane protein (downstream *exoR*; upstream *xthA2*)
  F8             236        1830765              1831000        intra           SMc00262                       putative 3-ketoacyl-CoA thiolase
  F9             166        2587012              2587177        intra           SMc02733                        
  F10            256        2991422              2991677        intra           SMc03993                        
  F11            128        3117150              3117277        intra           SMc03159 (*metN*)              methionine import ATP-binding protein
  F12            288        3303566              3303853        intra           SMc02491                        
  F13            184        3383057              3383240        inter           SMc03267                       putative dipeptidase (upstream ABC transporter)
  F14            143        3412878              3413020        inter           SMc03297                        
                            ***pSymB***                                                                         
  F15            184        1266                 1449           inter & intra   SMb21653 (*lacF*)              lactose ABC transporter, permease component
  F16            148        43628                43775          inter           SMb20032                        
  F17            150        132970               133119         inter           SMb20119                       putative site-specific recombinase
  F18            97         221089               221185         intra           SMb20213                       (upstream SMb20214)
  F19            67         492546               492612         intra           SMb20478                       putative dipeptide ABC transporter permease and ATP-binding protein
  F20            143        938297               938439         intra           SMb21188                       putative acyltransferase (*msbA2* operon)
  F21            141        1091213              1091353        intra & inter   SMb21151 /SMb21552 (*aacC4*)   putative aminoglycoside 6′-N-acetyltransferase
  F22            221        1588216              1588436        intra           SMb20574                       putative maltodextrin α-D-glucosyltransferase
  F23            145        1634582              1634726        intra           SMb20615 (*thiC*)              thiamine biosynthesis protein
                            ***pSymA***                                                                         
  F24            220        1186198              1186417        intra           SMa2103                        oxidoreductase
  F25            212        1278398              1278609        intra           SMa2295                        penicillin-binding protein
  F26            94         1305222              1305315        intra           SMa2337 (*rhtX*)               rhizobactin transporter
  F27            148        1305714              1305861        intra           SMa2337 (*rhtX*)               rhizobactin transporter

Potential functions of identified ChvI-regulated genes
------------------------------------------------------

Genes potentially regulated by ChvI are of diverse function (Table [1](#T1){ref-type="table"}). Because DNA fragments binding ChvI are often found within a coding sequence and not in intergenic areas, it is difficult to predict if ChvI acts as an activator of an adjacent gene or a repressor of the gene it binds within. In several cases, such as the rhizobactin gene cluster and the *msbA2* gene cluster, the ChvI-binding fragment is found in the first gene of what is predicted to be an operon. Table [1](#T1){ref-type="table"} lists genes found closest to a ChvI-binding DNA fragment but it is possible in many instances that genes further downstream could be part of the same transcript and also be ChvI-regulated. It is also important to note that the sequenced fragments are a subset of cloned fragments and other ChvI targets likely exist. Using the list of potentially ChvI-regulated genes obtained, we queried databases for functional relationships between targets: MetaCyc \[[@B21]\], KEGG \[[@B22]\] and STRING 8.1 \[[@B23]\]. Based on these analyses, a number of functional linkages may be made between some potential ChvI targets.

Two fragments (F15 and F6) are linked to lactose catabolism. One is found in front of the *lacFGZ1K* gene cluster and the second is found in SMc00589 (a conserved hypothetical protein), about 300 bp upstream of *gal* (Smc00588). The *lacFGZ1K* gene cluster encodes genes for lactose ABC-transporter and a β-galactosidase (E.C. 3.2.1.23). β-D-galactose is degraded through the De Ley-Doudoroff pathway in *S. meliloti*\[[@B24],[@B25]\] and *gal* codes for the galactose dehydrogenase (EC 1.1.1.48) of this pathway.

Two other fragments (F7 and F5) suggest that ChvI is involved in regulating phospholipid biosynthesis. One fragment is found in SMc02076 (*cls*) and another one is found in SMc00550, about 300 bp upstream of *psd* (SMc00551) and followed by *pssA* (SMc00552). Cardiolipin is produced in *S. meliloti* and the only gene coding for a cardiolipin synthetase is *cls*\[[@B26]\]. Interestingly, this gene is located about 1 kb downstream of the *exoS*-associated gene *exoR*. Proteins encoded by *psd* (phosphatidylcholine decarboxylase) and *pssA* (phosphatidylserine synthase) are responsible for the biosynthesis of phosphatidylethanolamine and phosphatidylserine respectively, and both of these phospholipids are also intermediates for phosphatidylcholine biosynthesis \[[@B27]\]. Mutants of these genes exhibit deficiencies in alfalfa symbiosis \[[@B27]\]. Aside from phospholipids synthesis, another link was found between SMc00550 and *msbA2* using STRING 8.1. These two genes are homologs and might have similar functions. The fragment F8 found in SMc00262, a putative 3-ketoacyl-CoA thiolase, followed by SMc00261, a putative fatty-acid-CoA ligase, also suggests regulation of lipid metabolism. These genes are putatively involved in fatty acid β-oxidation.

ChvI was also found to bind fragments from genes involved in peptide and methionine transport. A fragment (F13) belongs to the upstream sequence of SMc03267 and four genes encoding a putative dipeptidase and a putative dipeptide ABC-type transporter. Another fragment (F19) is from SMb20478, part of a gene cluster coding for another dipeptide ABC-transporter. MetN involved in importing methionine also has a fragment of its gene having affinity for ChvI.

A fragment found in *thiC* (F23) and another found in *hisB* (F1) do not present a directly evident link between the thiamine and histidine biosynthesis pathways they are respectively involved in but there is an indirect metabolic link that can be followed in MetaCyc, KEGG and in STRING. ThiC catalyzes the reaction between 5-aminoimidazole ribonucleotide (AIR) and hydroxymethylpyrimidine phosphate (HMP-P) in the thiamine biosynthesis pathway (Figure [1](#F1){ref-type="fig"}). AIR is biosynthesized from 5-phosphoribosyl 1-pyrophosphate (PRPP). PRPP is also required for the synthesis of histidine. In STRING this link is made through *pur* genes, which code for enzymes involved in purine synthesis. Pyrimidine, purine and pyridine nucleotide synthesis pathways are all dependent on the availability of PRPP.

![**5-Phosphoribosyl 1-pyrophosphate (PRPP) metabolic pathway and the potential role of ChvI in regulating downstream biosynthesis pathways.** Grey boxes represent genes potentially regulated by ChvI. Uridine-5'-phosphate (UMP), uridine-5'-diphosphate (UDP), uridine-5'-triphosphate (UTP), hydroxymethylpyrimidine phosphate (HMP-P), 4-amino-5-hydroxymethyl-2-methylpyrimidine-pyrophosphate (HMP-PP), 4-methyl-5-(β-hydroxyethyl)thiazole phosphate (THZ-P), 5-phospho-β-D-ribosyl-amine (PRA), 5-phospho-ribosyl-glycineamide (GAR), 5'-phosphoribosyl-N-formylglycineamide (FGAR), 5-phosphoribosyl-N-formylglycineamidine (FGAM), 5-aminoimidazole ribonucleotide (AIR), 4-carboxyaminoimidazole ribonucleotide (CAIR), 5'-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimidazole (SAICAR), aminoimidazole carboxamide ribonucleotide (AICAR), phosphoribosyl-formamido-carboxamide (FAICAR), inosine-5'-phosphate (IMP), phosphoribosyl-ATP (PR-ATP), phosphoribosyl-AMP (PR-AMP), phosphoribosylformiminoAICAR-P (PRoFAR), phosphoribulosylformimino-AICAR-P (PRFAR), D-erythro-imidazole-glycerol-phosphate (IGP).](1471-2180-13-132-1){#F1}

Following these analyses, we could not find a direct link between these potentially ChvI-regulated genes and the exopolysaccharide biosynthesis pathways, central to one of the most important phenotypes of the *chvI* mutant strain \[[@B10]\]. This is absolutely consistent with other experimental work that has failed to find direct binding of ChvI to exopolysaccharide synthesis gene upstream regions \[[@B17]\]. However, an indirect link is suggested from the regulation of thiamine and histidine biosynthesis (Figure [1](#F1){ref-type="fig"}). These pathways are inter-related with the synthesis of pyrimidine and consequently the availability of UTP required for the synthesis of UDP-glucose. Perhaps the imbalance caused by deregulating thiamine and histidine synthesis affects UDP-glucose synthesis and therefore polysaccharide production. To test this hypothesis, we added 0.1% uracil to the MM9-succinate minimal media and this improved significantly the growth of the *chvI* mutant strain, although still not to a level comparable to the wild-type (Table [2](#T2){ref-type="table"}). However, an important finding from these experiments is that the addition of uracil allows the *chvI* null mutant strain to grow in liquid media. From carbon source utilization analyses performed in a previous work \[[@B10]\], proline or ornithine are good carbon sources for the *chvI* mutant strains, therefore 0.1% proline was added to MM9-succinate media supplemented also with 0.1% uracil. This improved the growth of the mutant strain even further (Table [2](#T2){ref-type="table"}).

###### 

**Growth rate constants of*chvI261*mutant strain grown in MM9-succinate liquid media and with the addition of uracil and/or proline to the growth media**

  **Addition to medium**     **Strains**   
  ------------------------ --------------- ---------------
  none                      0.182 ± 0.004   0.043 ± 0.003
  uracil                    0.167 ± 0.006   0.144 ± 0.004
  uracil and proline        0.192 ± 0.003   0.161 ± 0.002
  proline                   0.201 ± 0.014   0.159 ± 0.025

Errors represent standard deviation.

Confirmation of ChvI involvement in transcriptional regulation of identified target genes
-----------------------------------------------------------------------------------------

Having identified genes that might be regulated by ChvI and conditions allowing the growth of the *chvI* mutant strain in liquid media, we used strains from a *S. meliloti* fusion library \[[@B20]\] to confirm the regulation at transcriptional levels. The library had been constructed using a vector that forms gene fusions to the reporter genes *gfp+/lacZ* or *gusA/tdimer2(12)* depending on the orientation of the insert. Because of the possible involvement of ChvI in regulating the *S. meliloti lac* operon, we selected *gusA* fusion strains to measure transcriptional activity using the β-glucuronidase assay. Gene fusions were transduced into *chvI* mutant SmUW38 and into the wild-type strain Rm1021, and then assayed for β-glucuronidase activity and compared. These assays have been applied to three operons identified by the DNA binding assays, confirming the regulation of all three operons by ChvI, and also demonstrating that ChvI can function as either an activator or a repressor, depending on the target gene. The transcription assay with a housekeeping gene in the two genetic backgrounds (wild-type versus *chvI261*) was not tested. However, we did examine expression of the gene SMa2295 with a fusion upstream of the ChvI binding site and the results showed low and not significant GusA activity difference between the two genotype backgrounds (23 versus 30 Miller Units).

ChvI-bound fragment F20 was identified within SMb21188, the first gene of a predicted four-gene operon, and therefore we tested three gene fusions to SMb21189, SMb21190, and *msbA2* (SMb21191) (Figure [2](#F2){ref-type="fig"}B). These fusions had a much higher expression level in the wild-type than in *chvI* mutant background (Figure [2](#F2){ref-type="fig"}A). These results suggest that ChvI is responsible for activation of the co-transcription of SMb21189, SMb21190, and *msbA2* genes. Using a neural network promoter prediction tool \[[@B28]\], we predicted a putative transcriptional start site (P2) adjacent to the area containing a ChvI binding site (B). Another putative transcriptional start site (P1) further upstream from SMb21188 suggests that transcription might be directed from two differently regulated promoters, only one of which would include the SMb21188 gene.

![**Transcriptional fusion assays and the*msbA2*operon.** (**A**) GusA activities were measured for fusions in genes SMb21189, SMb21190, and *msbA2* in wild-type (Rm1021) and *chvI261* mutant (SmUW38) strain backgrounds. No GusA activities above background levels were detected for fusions to SMb21189 and SMb21190 in the *chvI261* mutant strain background. (**B**) In the operon diagram, F1, F2, and F3 represent the positions of the fusions to SMb21189, SMb21190 and *msbA2* respectively. The grey box (**B**) represents the region for ChvI binding, and P1 and P2 are predicted promoters.](1471-2180-13-132-2){#F2}

Reporter gene fusion assays and promoter prediction were done with fusions in genes SMc00262 and SMc00261, which are predicted to encode a 3-ketoacyl-CoA thiolase and a fatty-acid-CoA ligase respectively (Figure [3](#F3){ref-type="fig"}B). In this case, a promoter was predicted immediately upstream of the ChvI binding area in SMc00262 and accordingly the fusions further downstream in SMc00262 and in SMc00261 presented higher expression levels in *chvI* mutant strains than in wild type (Figure [3](#F3){ref-type="fig"}A). These results suggest that ChvI acts by repressing the transcription of the SMc00264 -- SMc00259 operon.

![**Transcriptional fusion assays and the SMc00261 operon.** (**A**) GusA activities were measured for fusions in genes SMc00262 and SMc00261 in wild-type (Rm1021) and *chvI261* mutant (SmUW38) strain backgrounds. (**B**) In the operon diagram, F1 and F2 represent the position of the fusions to SMc00262 and SMc00261 respectively. The grey box (**B**) represents the region for ChvI binding, and P1, P2 and P3 are predicted promoters.](1471-2180-13-132-3){#F3}

*S. meliloti* produces an iron-siderophore, rhizobactin 1021, under iron-depleted conditions \[[@B29]\]. Genes for the synthesis and transport of rhizobactin are clustered in an operon \[[@B30]\]. The rhizobactin transporter coding sequence (*rhtX*, SMa2337) was found to contain two DNA fragments binding ChvI (Table [1](#T1){ref-type="table"} and Figure [4](#F4){ref-type="fig"}B). We tested a fusion following the first binding site (B1) and two other fusions further in *rhbB* (SMa2402; diaminobutyrate decarboxylase, EC 4.1.1.86) and in *rhbF* (SMa2410). The promoter prediction suggests the presence of a promoter before *rhtX* and another one before *rhbA*. The β-glucuronidase assays presented a higher expression in *chvI* background for all three fusions. This suggests that ChvI represses the expression of genes required for the synthesis and transport of rhizobactin 1021. Both binding areas seem to be important in repressing the transcription as shown by a higher expression in the fusion found before the second binding.

![**Transcriptional fusion assays and the rhizobactin operon.** (**A**) GusA activities were measured for fusions in genes *rhtX*, *rhbB* and *rhbF* in wild-type (Rm1021) and *chvI261* mutant (SmUW38) strain backgrounds. (**B**) The rhizobactin genes are clustered in one operon, F1 F2 and F3 represent the positions of the fusions to *rhtX*, *rhtB*, and *rhbF* respectively. The grey boxes (B1 and B2) represent the possible position for ChvI binding, and P1 and P2 are predicted promoters.](1471-2180-13-132-4){#F4}

The high basal level of the negatively regulated operons is not really unexpected given that we do not know the repressing conditions, and also the likelihood of multiple regulatory systems acting on these genes. These experiments involved the comparison of gene expression in genetic backgrounds that resulted in differences only in the presence / absence of the ChvI regulator. Otherwise, the environmental conditions were not altered.

Discussion
==========

An adaptation of methods to perform gel electrophoresis mobility shift assays allowed us to identify DNA fragments with higher affinity for ChvI. Analyses of these results force us to revise our earlier perceptions following phenotypic analyses of ExoS/ChvI as mainly a regulatory system for exopolysaccharide production. Our results suggest that the ChvI regulon includes genes from diverse pathways. Moreover, ChvI appears to have a dual regulatory role, activating and repressing different operons. The total number of targets likely far outnumbers the 27 fragments that we pulled out in our screen, especially considering that we did not hit the same fragment more than once, and we also did not find a few other targets that had previously been shown to be bound by ChvI.

The approach used in our study is highly complementary to the microarray and directed DNA binding study of Chen et al. \[[@B17]\] that resulted in the identification of several potential regulatory targets of ExoS/ChvI and the prediction of a consensus binding sequence. It is important to note, however, that of 19 upstream regions tested, binding was only detected to three (*ropB1*, SMb21440, SMc01580), and a putative consensus sequence was determined using some upstream regions to which binding had not been demonstrated. Confirmation of this consensus binding sequence awaits more detailed DNA footprinting experiments on a larger number of identified targets. It is possible that many ChvI-repressed genes may not have been detected in that study due to the use of a constitutively activated variant of the ChvI protein that might not have been able to function as a repressor.

The binding of ChvI within SMa2337 (*rhtX*) to repress *rhtXrhbABCDEF* gene transcription could suggest that following the sensing of a signal other than the presence of iron, ExoS/ChvI represses genes for rhizobactin 1021 production. This operon is known to be upregulated by RhrA in iron-depleted conditions \[[@B31]\] and downregulated by RirA in iron-replete conditions \[[@B32]\]. Our fusion assay results confirmed that the rhizobactin operon is highly expressed in M9-minimal media (iron-depleted conditions). However, this expression is even higher in strains with the *chvI* null mutation. Iron is an important micronutrient found in many cofactors required for cytochrome and nitrogenase activity. Its acquisition however is difficult for two main reasons. First, it is poorly soluble at pH 7, and secondly, a high concentration of iron can cause the generation of hydroxy radicals. Bacteria produce siderophores to scavenge iron and therefore control iron availability. A tight control over the production of siderophore is thus important. The lack or the overproduction of rhizobactin 1021 by *S. meliloti* impairs the symbiotic relationship with alfalfa \[[@B29]\]. Mutation of *rirA* derepresses rhizobactin production and as a result causes a growth defect of the strain relative to the presence of iron \[[@B33]\]. The reduced viability of the *rirA* mutant due to oxidative stress suggested that perhaps this strain would also be affected in its symbiotic properties but it was not the case \[[@B33]\]. This study suggested that in planta another unknown regulatory system might control the production of rhizobactin. Whether ExoS/ChvI might be the system responsible awaits further investigation.

Another important finding is the confirmation that ChvI is involved in activation of the expression of SMb21189, SMb21190, and *msbA2*. These genes have only been described recently in the literature although *msbA2* in particular may play an important but incompletely defined role in symbiosis \[[@B34],[@B35]\], and the operon has already been shown to be subject to ChvI regulation \[[@B17]\]. SMb21189 and SMb21190 encode glycosyltransferases and *msbA2* is part of an ABC-transporter family involved in macromolecule export. The above mentioned recent studies proposed that the operon including SMb21188, a putative acyltransferase, is involved in the production and export of an unknown polysaccharide which uses intermediates from the succinoglycan production pathway. The regulation of this operon by ExoS/ChvI is therefore the closest link to the succinoglycan-deficient phenotype of *exoS* and *chvI* mutant strains. Although this ChvI-regulated operon is not required for succinoglycan production it seems to be functionally related to succinoglycan production.

The third operon that we confirmed to be differentially regulated by ChvI encodes proteins putatively involved in fatty acid β-oxidation. SMc00262 putatively produces a 3-ketoacyl-CoA and SMc00261, a fatty-acid-CoA ligase. These genes are also followed by SMc00260 coding for a putative short-chain dehydrogenase and SMc00259 coding for a hypothetical protein. Upstream of these genes lay genes for a transcriptional regulator of the IclR family (SMc00263) and another short-chain dehydrogenase (SMc00264). Our earlier studies failed to demonstrate a phenotype for SMc00260 and SMc00264 mutants \[[@B36]\]. A tripartite ATP-independent periplasmic (TRAP) transporter system upregulated by the presence of acetoacetate and 3-methyl oxovaleric acid is encoded by genes in the same orientation upstream of SMc00264 \[[@B37]\]. All these genes are organized in the same orientation and close enough to each other to be part of the same transcript. However, our finding of a ChvI binding site in SMc00262, after the gene encoding the IclR regulator, suggests a complex regulation of these genes. In fact, a N-Acyl homoserine lactone (AHL) also impacts on their expression \[[@B38]\]. The fatty-acid-CoA ligase (SMc00261) has been found differentially accumulated in early log phase cultures of *S. meliloti* Rm1021 treated for 2 hours with 3-oxo-C16:1-HL while the periplasmic binding protein (SMc00265) accumulated in stationary phase cultures independently of the presence of AHLs. Perhaps under conditions that activate ChvI, the first part of the gene cluster is upregulated to allow the import of an organic acid but the second part responsible for its degradation and entry in the TCA cycle is downregulated. This hypothesis would suggest the use of this organic acid, under certain conditions, as a readily available building block rather than an energy source.

An important finding from this work is that uracil and proline improved the growth of the *chvI* mutant. This finding now allows us to culture the mutant strain in liquid media, greatly facilitating experimental analysis. Binding of ChvI in *thiC* (SMb20615) and in *hisB* (SMc02574), perhaps to repress the thiamine and histidine biosynthesis operons, made us hypothesize that a derepression of these operons in *exoS* or *chvI* mutants could lead to a deficiency in UTP formation and could explain the pleiotropy of these mutants. Rhizobial purine and pyrimidine auxotrophic mutants have been found affected in polysaccharides synthesis and plant invasion \[[@B39]-[@B42]\]. Further work needs to be done to confirm that *chvI* mutant auxotrophy is truly caused by a derepression of operons for thiamine and histidine biosynthesis.

Conclusions
===========

We have identified a number of putative direct targets of ChvI, many of which are consistent with the pleotropic phenotype of *exoS* and *chvI* mutants. We also demonstrated that ChvI may act as a repressor or activator of gene expression, and surprisingly ChvI seems to often bind within predicted protein coding sequences. The bias is often to only consider intergenic regions for locations of potential regulatory sites. However, we note that the Fur regulator of *Helicobacter pylori* is just one example of a transcriptional regulatory protein that has targets within polycistronic operons and acts as a repressor and an activator of gene expression \[[@B43]\]. The tendency to search for transcriptional cis-regulatory elements in intergenic areas rather than considering equally regions internal to ORFs may need to be revisited. GD.EMSA or Chromatin-Immunoprecipitation (ChIP) techniques are examples of techniques that do not have a bias towards intergenic or intragenic areas and their usage certainly make important contributions to our knowledge about transcriptional regulation.

Although this study has uncovered new facets of the ExoS/ChvI regulation, the regulatory signal is still unknown. However, a number of new hypotheses emerge. Several genes identified in this study as possibly ChvI-regulated are involved in amino acid and peptide metabolism and transport. In *Rhizobium leguminosarum* bv. *viciae* VF39SM, peptides have been shown to increase the expression of the outer membrane protein *ropB* in a ChvG-dependent manner \[[@B44]\]. Perhaps ExoS and/or ExoR sense(s) peptides. Also, our work suggests a direct regulatory link between the PTS and the ExoS/ChvI systems; do these systems partner to coordinate the C and N metabolism as suggested by recent work in *B. melitensis*\[[@B45]\]? With several putative ChvI-targeted genes now identified, tools necessary to test these hypotheses are available. We are cognizant, however, of the fact that our screen was not saturating, and we will endeavor to adapt the method for higher throughput so that we have a better understanding of the complete ChvI regulon and the nature of the ChvI consensus binding sequence.

Methods
=======

Bacterial strains, plasmids and growth conditions
-------------------------------------------------

Strains and plasmids used in this study are listed in Table [3](#T3){ref-type="table"}. Growth conditions are as described previously \[[@B10]\] or as described in subsequent procedures.

###### 

Bacterial strains, plasmids and primers used in this study

  **Strain/Plasmid/Primer**   **Relevant characteristics**                                                                                                                **Reference or source**
  --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  *Sinorhizobium meliloti*                                                                                                                                                 
  Rm1021                      SU47 *str-21*, Sm^r^ wild type                                                                                                              \[[@B46],[@B47]\]
  SmUW38                      Rm1021 *chvI*::*nptII* (*chvI261*)                                                                                                          \[[@B10]\]
  SmFL430                     RmP110 SMa2295::pTH1522                                                                                                                     \[[@B20]\]
  SmFL112                     RmP110 *msbA2*::pTH1522                                                                                                                     \[[@B20]\]
  SmFL4665                    RmP110 SMb21189::pTH1522                                                                                                                    \[[@B20]\]
  SmFL5401                    RmP110 SMb21190::pTH1522                                                                                                                    \[[@B20]\]
  SmFL918                     RmP110 SMc00262::pTH1522                                                                                                                    \[[@B20]\]
  SmFL4392                    RmP110 SMc00261::pTH1522                                                                                                                    \[[@B20]\]
  SmFL2950                    RmP110 *rhbB*::pTH1522                                                                                                                      \[[@B20]\]
  SmFL5628                    RmP110 *rhtX*::pTH1522                                                                                                                      \[[@B20]\]
  SmFL5755                    RmP110 *rhbF*::pTH1522                                                                                                                      \[[@B20]\]
  SmUW45                      Rm1021 SMa2295::pTH1522                                                                                                                     This study
  SmUW43                      Rm1021 *msbA2*::pTH1522                                                                                                                     This study
  SmUW58                      Rm1021 SMb21189::pTH1522                                                                                                                    This study
  SmUW59                      Rm1021 SMb21190::pTH1522                                                                                                                    This study
  SmUW46                      Rm1021 SMc00262::pTH1522                                                                                                                    This study
  SmUW57                      Rm1021 SMc00261::pTH1522                                                                                                                    This study
  SmUW55                      Rm1021 *rhbB*::pTH1522                                                                                                                      This study
  SmUW62                      Rm1021 *rhtX*::pTH1522                                                                                                                      This study
  SmUW63                      Rm1021 *rhbF*::pTH1522                                                                                                                      This study
  SmUW157                     SmUW38 SMa2295::pTH1522                                                                                                                     This study
  SmUW133                     SmUW38 *msbA2*::pTH1522                                                                                                                     This study
  SmUW148                     SmUW38 SMb21189::pTH1522                                                                                                                    This study
  SmUW149                     SmUW38 SMb21190::pTH1522                                                                                                                    This study
  SmUW136                     SmUW38 SMc00262::pTH1522                                                                                                                    This study
  SmUW147                     SmUW38 SMc00261::pTH1522                                                                                                                    This study
  SmUW145                     SmUW38 *rhbB*::pTH1522                                                                                                                      This study
  SmUW152                     SmUW38 *rhtX*::pTH1522                                                                                                                      This study
  SmUW153                     SmUW38 *rhbF*::pTH1522                                                                                                                      This study
  *Escherichia coli*                                                                                                                                                       
  DH5α                        F^-^, φ80d*lac*Z∆M15, *end*A1, *rec*A1∆(*lac*ZYA-*arg*F)U169, *hsd*R17(r~K~^-^ m~K~^+^), *deo*R, thi-1, *sup*E44, λ^-^, *gyr*A96, *rel*A1   \[[@B48]\]
  BL21(DE3)pLysS              F^−^, *ompT*, *hsdS*~B~ (r~B~^-^, m~B~^-^), *dcm*, *gal*, λ(DE3), pLysS, Cm^r^                                                              \[[@B49]\]
  ***Plasmid***                                                                                                                                                            
  pGEM®-T Easy                Cloning of PCR products, Amp^r^                                                                                                             Promega (USA)
  pET-30a(+)                  His•Tag expression vector, Km^r^                                                                                                            EMD Chemicals (Novagen)
  pLB010                      pGEM®-T Easy::*chvI*, Amp^r^                                                                                                                This study
  pJF011                      pET-30a(+)::*chvI*, Km^r^                                                                                                                   This study
  pUC18                       Cloning vector, Amp^r^                                                                                                                      \[[@B50]\]
  pTC198                      pUC19::5-kb *chvI-exoShrpK*, Amp^r^                                                                                                         \[[@B10]\]
  pTC190                      pVK101::4kb *A. tumefaciens chvI/G*, Tc^r^ Km^r^                                                                                            \[[@B4]\]
  pKNG101                     *sacB*^+^*mob*RK2 *ori*~R6K~, Sm^r^                                                                                                         \[[@B51]\]
  pKD001                      pTC190::pKNG101, Tc^r^                                                                                                                      This study
  ***Primer***                ***Sequence (*5′-3′*)***                                                                                                                     
  LB5                         atgcagaccatcgcgctt                                                                                                                          This study
  LB6                         acatcgtgatccaacaagg                                                                                                                         This study
  LB61                        gtaaaacgacggccagt                                                                                                                           This study

*Cloning of* chvI *for His•Tag-ChvI expression and purification*
----------------------------------------------------------------

*S. meliloti* Rm1021 *chvI* was PCR amplified using primers LB5 and LB6 (Table [3](#T3){ref-type="table"}). The 800-bp PCR fragment was gel-purified and then cloned in pGEM®-T Easy vector. Plasmid pLB010 with the insert in the correct orientation for expression was verified by DNA sequence analysis. NotI *chvI*-containing fragment was then cut out of pLB010 and ligated to NotI-digested pET-30a, generating a N-terminal His•Tag fusion pJF011. *E. coli* BL21(DE3)pLysS clones carrying the pJF011 plasmid were confirmed for His•Tag-ChvI production by western blot using a His•Tag monoclonal antibody from mouse (Novagen) and Alexa Fluor 488 goat anti-mouse IgG (H + L) (Invitrogen, Molecular Probes) as the secondary antibody. His•Tag-ChvI purification using nickel-affinity chromatography was performed in the laboratory of Professor Bi-Cheng Wang at University of Georgia (USA).

Electrophoretic mobility shift assay using genomic DNA (GD.EMSA)
----------------------------------------------------------------

To prepare samples, *S. meliloti* Rm1021 genomic DNA was digested to completion by overnight incubation with Bsp143I restriction enzyme (Sau3AI isoschizomer, Fermentas Life Sciences, Canada) and the reaction was then heat-inactivated. Purified His•Tag-ChvI protein was mixed with digested DNA in a solution of 9% glycerol, 3 mM acetyl phosphate, 0.8 mM Tris-acetate, 0.25 mM magnesium acetate, 1.65 mM potassium acetate, 2.5 μg ml^-1^ bovine serum albumin (BSA). For negative controls, ChvI protein was not added to samples. Incubations were carried out for 30 minutes at room temperature and loaded directly on gel without dye.

To perform the electrophoresis, a sodium boric acid buffer (SB buffer) was made following the specifications of Brody and Kern \[[@B52]\]. 5% nondenaturing polyacrylamide gels (14 cm × 16 cm) were cast using a Hoefer SE 600 gel electrophoresis unit and following the standard procedure for resolution of small DNA fragments \[[@B53]\] but using SB buffer instead of TBE buffer. Gels were run in 1X SB buffer between 25 to 40 mA for 3--6 hours. Gels were then stained for 1 hour in a 3X GelRed™ staining solution containing 0.1 M NaCl and following manufacturer's recommendation for post gel staining (Biotium, USA, CA) prior to visualization on a UV transilluminator. Shifted DNA bands in the highest part of the gel were then excised and stored in 2-ml plastic tubes at −20°C.

To recover DNA fragments from polyacrylamide gel, the method from Ausubel et *al*. (1992) \[[@B53]\] was used. The elution buffer used contained 0.5 M ammonium acetate, 1 mM EDTA, 0.1% SDS and final pH 8. 200 μl elution buffer was added to each tube containing a piece of gel. The gel was then crushed in smaller pieces using a pipet tip. Tubes were incubated overnight at 37°C with shaking. Following centrifugation in a microcentrifuge at room temperature for 10 minutes at 10,000 rpm, supernatant was removed and transferred to a clean 2.0 ml tube. Ethanol (500 μl) was added to precipitate the DNA and tubes were placed at −20°C overnight. DNA was pelleted at 13,000 rpm for 10 minutes. Supernatant was removed and DNA solubilized in 100 μl of 10 mM Tris pH 8 and 15 μl of 5 M sodium chloride was added. DNA was then precipitated a second time with 2 volumes of ethanol and kept overnight at −20°C. Precipitated DNA was recovered by centrifugation in a microcentrifuge at 13,000 rpm for 15 minutes, supernatant was removed and DNA was dried. Final resuspension of DNA was done with 10 μl of 10 mM Tris pH 8.

The DNA fragments were cloned into the BamHI site in pUC18. Prior to ligation, BamHI-digested pUC18 was dephosphorylated using shrimp alkaline phosphatase (Fermentas Inc.) and the reaction stopped by heat-inactivation. Ligation was performed overnight at room temperature with T4 DNA ligase (Fermentas Inc.). Transformation of calcium chloride competent *E. coli* DH5α cells was done following standard procedure \[[@B54]\]. Over 40 transformant colonies were streak-purified from each experiment. A selection of them were then used for plasmid preparation and tested for the presence of an insert using restriction digest with EcoRI and PstI. Fragments cloned in pUC18 were sequenced using primers M13F provided by the sequencing facility (University of Waterloo) or LB61 (Table [3](#T3){ref-type="table"}).

Sequences were first analyzed by searching for Sau3AI (Bsp143I) restriction sites to determine the limits of each fragment. Each fragment sequence was then searched against *S. meliloti* Rm1021 genomic sequence using the BLAST tool from Toulouse annotation website \[[@B55]\]. Genes in closest proximity to identified sequences and potentially regulated by ChvI were searched against STRING 8.1 databases (June 28, 2009) for functional relations \[[@B23]\]. The search was directed from the Toulouse annotation website.

Reporter gene fusion strains
----------------------------

Transcriptional fusion strains were obtained by transduction from the reporter gene fusion library strains made by Cowie *et al*. \[[@B20]\]. SmFL strains were used to prepare transduction lysates to transfer the gene fusions from the original *S. meliloti* RmP110 background into the Rm1021 background. Selection of transductants was done on LB with gentamicin (60 μg ml^-1^). The same lysates were also used to transduce gene fusions into SmUW38 (pKD001) with selection on LB gentamicin (60 μg ml^-1^) and neomycin (200 μg ml^-1^). Four transductants per transduction experiment were picked and streaked on LB gentamicin and neomycin. Transductants were then cured of pKD001 by streaking them on MM9-succinate gentamicin (20 μg ml^-1^) containing 2.5% sucrose and incubated at 30°C for four days. pDK001-cured strains were finally streaked on MM9-succinate gentamicin.

Phage ΦM12 was used for transductions following the usual procedure \[[@B56]\], except that TY media was used instead of LBmc media to prepare and dilute lysates. High yield of transductants required the use of Bacto™-Agar, -Tryptone, and -Yeast extract (BD). Diluted lysate (0.5 ml) was mixed with equal volume of cell suspension and incubated at room temperature for 30 minutes. Cells were then recovered by centrifugation in a microcentrifuge for 10 minutes and washed twice with 2 ml of saline. Final resuspension was done with 400 μl saline and then spread on two agar plates. Plates were incubated at 30°C for four days.

Growth in liquid media
----------------------

Inocula were prepared by resuspending bacterial biomass from MM9-succinate-agar plates into a saline solution (0.85% NaCl) to obtain an optical density (OD~600~) of 0.8. Test tubes containing 5-ml liquid media made of MM9-succinate with/without 0.1% proline and/or 0.1% uracil where inoculated with the inoculum at a 10% concentration. Test tubes were incubated at 30°C with constant shaking. Growth was monitored by reading the absorbance at 600 nm. Growth rate constants (μ) were calculated based on absorbance values during the exponential growth phase and using the formula: μ = ( (log~10~ N - log~10~ N~0~) 2.303) / (t - t~0~). Results represent the average of duplicates and the standard deviation was calculated as the error.

β-Glucuronidase assay
---------------------

To measure transcription from reporter gene fusion strains, the β-glucuronidase assay described in Cowie et al. \[[@B20]\] was adapted. Strains were grown in MM9-succinate plus 0.1% proline, 0.1% uracil, and gentamicin until OD~600~ of 0.2 - 0.8. These cells were then used directly for the assay in microplates as described previously \[[@B20]\]. Assays were done in triplicate and standard deviation calculated.
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###### Additional file 1

**Gel image of PD.EMSA to compare DNA shifts on 6-cm versus 14-cm 5% nondenaturing polyacrylamide gel and using SB buffer.** Prior to the electrophoresis, the Bsp143I restricted pTC198 plasmid was incubated or not with the HisTag-ChvI protein.

###### 
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###### Additional file 2

**Gel image of PD.EMSA to compare ChvI binding specificity in presence of EDTA or acetylphosphate.** A 5% nondenaturing polyacrylamide gel made with TB buffer was used for the electrophoresis of the EcoRI-PstI double restricted pLB102 plasmid. The plasmid DNA was incubated or not with HisTag-ChvI protein in presence or not of EDTA and in presence or not of acetylphosphate (AP) prior to the electrophoresis.
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